Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, Joaquim; de Wit, Ronald; J. Vaughn, David; Fradet, Yves; Lee, Jae‐Lyun; Fong, Lawrence; J. Vogelzang, Nicholas; Ángel Climent, Miguel; P. Petrylak, Daniel; K. Choueiri, Toni; Necchi, Andrea; R. Gerritsen, Winald; Gurney, Howard; I. Quinn, David; Culine, Stéphane; N. Sternberg, Cora; Mai, Yabing; Poehlein, Christian; F. Perini, Rodolfo; F. Bajorin, Dean

doi:10.1056/nejmoa1613683

Public

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Published in New England Journal of Medicine • Feb 17, 2017

Authors:

Joaquim Bellmunt

Ronald de Wit

David J. Vaughn

Abstract

BACKGROUND: Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. METHODS: In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or...

Subject

Medicine

Pembrolizumab

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!